With Roche out the door, Chiasma is raising $56M to go it alone

Damian Garde

In early 2013, signed a $ 595 million deal with Israel's with eyes on its promising treatment for the hormone disorder acromegaly. But the Swiss drugmaker got cold feet over the summer, and now is picking up the pieces, cash in hopes of submitting its drug to regulators this year.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS